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1) Inadequately fine-grained phenotyping of subjects
2) Ignoring the important moderating role of BBB permeability
3) Choosing subjects at ‘too late’ a stage of illness
4) Inadequately sensitive antibody detection assays
38.3 ONGOING GERMINAL CENTRE REACTIONS 
CONTRIBUTE TO N-METHYL-D-ASPARTATE 
RECEPTOR (NMDAR) ANTIBODY PRODUCTION 
IN NMDAR-ANTIBODY ENCEPHALITIS
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Background: Immunoglobulin G (IgG) against the NR1-subunit of the 
N-methyl-D-aspartate (NMDAR) receptor mediates NMDAR-antibody 
encephalitis (NMDAR-Ab-E). This multi-stage illness presents with an 
acute severe psychiatric syndrome, alongside other neurological features, 
similar to human and animal NMDAR antagonist models. The disease is 
associated with an ovarian teratoma in around 20% of cases. The cellu-
lar immunity underlying this disease is not well understood. While anti-
body-modifying immunotherapies often promote disease resolution, the 
illness can be refractory to these treatments correlating with sub-optimal 
outcomes.
NR1-IgG can be detected several years after clinical resolution, which may 
be via ongoing germinal centre reactions or the establishment of antibody-
secreting cells as long-lived plasma cells in bone marrow niches. These two 
divergent models implicate use of differing immunotherapies to target these 
cells. Here we investigate the contribution of ongoing germinal centre reac-
tions to disease progression, potentially informing disease mechanisms and 
guide targeted immunotherapy.
Methods: We hypothesised that recurrent antigen-driven germinal cen-
tre reactions would be associated with active generation of  NR1-specific 
IgM and IgG and NR1-specific circulating B cells. We validated a NR1-
IgM cell based assay establishing specificity cut-offs by screening healthy 
and disease control cohorts alongside a previously collected NMDAR-
Ab-E cohort (n=46). Following this we went on to explore the tempo-
ral evolution of  NR1-IgG and NR1-IgM titres in a prospective cohort 
(n=12).
To investigate the lymphocyte characteristics, we stimulated ovarian ter-
atoma lymphocytes and peripheral blood mononuclear cells (PBMCs) 
from multiple time points under varying cytokine conditions to understand 
whether these circulating cells showed capacity for NR1-IgG and IgM 
generation.
Results: We found a 43% prevalence rate of NR1-IgM in the historic 
cohort. We then confirmed that NR1-IgM binding was specific by its selec-
tive depletion after anti-IgM precipitation but not with protein G. In the 
prospective cohort, we noted often high titres of IgM (up to 1:500) most 
commonly early in the disease but persisting for around 2 years. NR1-IgM 
levels varied in titre alongside NR1-IgG spikes. Consistently, culture experi-
ments of patient lymphocytes (PBMCs and tumour-derived) produced 
varying degrees of NR1-IgM and NR1-IgG under conditions associated 
with B cell proliferation. The NR1-IgG levels correlated with serum NR1-
titres suggesting these circulating B cells made a proportional contribution 
to serum levels.
Discussion: Ongoing germinal centre reactions likely contribute much 
of the circulating NR1-specific B cell population in NMDAR-Ab-E. 
Autoimmunisation at these centres represents an as yet unexplored ther-
apeutic target in this and potentially other autoimmune encephalopathies. 
Regional specificity of these reactions including lymph nodes draining 
sources of NR1-antigen require further direct evaluation.
38.4 PREVALENCE OF ANTI-NEURONAL 
ANTIBODIES IN PATIENTS ADMITTED WITH 
FIRST EPISODE OF PSYCHOSIS AND THEIR 
CLINICAL OUTCOMES
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Background: Anti-neuronal antibodies are associated with psychosis 
although their clinical significance in first episode of psychosis (FEP) is 
undetermined. This study examined the prevalence of anti-neuronal anti-
bodies in patients admitted to hospital for treatment of their first episode 
of psychosis and described clinical presentations and treatment outcomes 
of those who were antibody positive.
Methods: Between July 2013 and May 2015, all consenting patients aged 
between 12 and 50 admitted for their first episode of psychosis to three 
mental health hospitals in Queensland, Australia, were tested for anti-neu-
ronal antibodies in serum. Antibody positive patients were referred for neu-
rological and immunological consultation and treatment.
Results: During the study, 154 FEP patients were admitted with their first 
episode of psychosis and 113 consented to participate. Six patients were 
found to have anti-neuronal antibodies; (anti-NMDAR antibodies [n = 4], 
VGKC antibody [n = 1], antibody against uncharacterised antigen [n = 1]). 
Of these, five received immunotherapy, leading to complete resolution of 
psychosis in four.
Discussion: A small, but significant subgroup of patients with first episode 
psychosis have anti-neuronal antibodies detectable in serum and evidence 
of central nervous system autoimmune pathology. Early identification of 
these patients and referral for appropriate treatment is critical to optimise 
recovery.
39. VIRUSES AND SCHIZOPHRENIA: 
IMPLICATIONS FOR PATHOPHYSIOLOGY AND 
TREATMENT
Alan Breier
Indiana University School of Medicine
Overall Abstract: The viral hypothesis of  schizophrenia posits that viral 
infections disrupts cortical circuits that give rise to schizophrenia psy-
chopathology. Prenatal viral exposure during key neurodevelopmental 
periods, either through direct effects on fetal brain or exposure to exces-
sive maternal cytokines and other chemokines, have been implicated. 
In addition, abnormal activation of  dormant neuro-viruses have been 
linked to the pathophysiology of  schizophrenia. Activation of  dormant 
viruses has potentially important treatment implication for therapies, 
such as valacyclovir, that suppress viral activity. Among the viruses that 
have been mostly frequently associated with schizophrenia include her-
pes simplex virus type 1 (HSV1) and Epstein-Barr virus (EBV). The 
purpose of  this symposium is to focus on the role of  viruses in the path-
ophysiology of  schizophrenia and results of  antiviral treatment trials in 
this illness.
Diana Perkins will present data from the North American Prodrome 
Longitudinal Study (NAPLS2) which is an eight-site observational study of 
predictors and mechanism of conversion to psychosis and is comprised of a 
cohort of 763 individuals at clinical high risk for developing psychosis. This 
paper examines methylation of promoter regions of genes associated with 
gene expression and reports that 10 markers correctly classified individuals 
who converted to psychosis. The SIRT1 gene, that is upregulated with HSV, 
was among the predictive markers.
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Faith Dickerson will focus on the association between HSV1 exposure and 
cognitive impairment in schizophrenia and the potential link between EBV 
and this illness. In a large cohort of 828 individuals and 573 controls, a 
significant relationship between HSV1 exposure and cognitive impairment 
was found. The strongest linkage was in the domain of immediate memory. 
In 397 subjects with schizophrenia who were compared to 289 controls, 
significantly higher levels of antibodies to the EBV viral capsid antigens 
(VCA) was discovered in the schizophrenia cohort.
Vishwajit Nimgaonkar will examine the relationship between HSV1 infec-
tion and cognitive performance in a mixed cohort of 226 individuals and 
present the results of a randomized clinical trial of the anti-viral agent 
valacyclovir. HSV1 infected participants had significantly lower scores on 
Emotion Identification and Discrimination (EMOD), spatial memory and 
spatial ability irrespective of schizophrenia diagnoses. Valacyclovir treat-
ment (1.5 grams BID, 16-week trial) improved EMOD.
Alan Breier will report the results of the VISTA study – 12-site, dou-
ble-blind, placebo controlled, 16-week trial of the anti-viral medication 
valacyclovir (3 grams/day) in early phase schizophrenia. 170 subjects were 
randomized of whom 74 were HSV-1 seropositive and 96 were seronega-
tive. Baseline working memory scores (letter number sequence) were sig-
nificantly lower in HSV1 positive as compared to HSV1 negative subjects. 
Analysis of valacyclovir treatment outcomes have only recently commenced 
and are ongoing. The complete data set (cognitive domains, role function, 
symptoms and safety) will be presented in full at the meeting.
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Background: A dysregulated immune system is implicated in the develop-
ment of psychotic disorders. Persons with schizophrenia have altered levels 
of circulating immune cell signaling molecules (cytokines), and elevation 
of specific cytokines predict conversion to psychosis in persons at clinical 
high risk. Whether these peripheral signals are a causal or a secondary phe-
nomenon is unclear. But, subpopulations of circulating immune cells do 
regulate the brain from meningeal and perivascular locations influencing 
cognition, mood, and behavior, and thus may be relevant to schizophre-
nia vulnerability. Hematopoietic stem cells in the bone marrow differentiate 
into cascading subtypes depending on signals from other organs, especially 
the brain. For example, a monocyte subpopulation emerges with repeated 
social defeat that establish the persistence of anxiety-like behaviors; block-
ing their release or inhibiting their attachment to brain vascular endothe-
lium prevents the emergence of anxiety-like behaviors. In humans, a similar 
monocyte subpopulation is associated with social isolation and other 
adversities including low SES, chronic stress, and bereavement.
Methods: The North American Prodrome Longitudinal Study (NAPLS2) is 
an eight-site observational study of predictors and mechanisms of conver-
sion to psychosis The full cohort includes 763 at clinical high risk (CHR) 
based on the Criteria of Prodromal State (COPS) and 279 demographi-
cally similar unaffected comparison (UC) subjects. Methylation of whole 
blood DNA collected in PAXgene tubes at baseline was analyzed with the 
Illumina 450k array in a subgroup of 59 subjects who converted to psycho-
sis (CHR-C), 84 CHR subjects followed for 2 years who did not develop 
psychosis (CHR-NC) and 67 unaffected subjects (UC). Our analyses 
focused on methylation of promoter regions of genes, associated with gene 
expression. Classifier construction used Coarse Approximation Linear 
Function (CALF) with bootstrapping of 1000 random 80% subsets with 
replacement to determine statistical likelihood.
Results: We found highly overlapping sets of differentially methylated 
promoter regions in CHR-C subjects compared to CHR-NC and to UC 
subjects. A  set of 10 markers correctly classified CHR-C and CHR-NC 
subjects with high accuracy (AUC=0.94, 95% CI 0.89–0.98). Included was 
SIRT1, a gene that is upregulated with HSV reactivation.
Discussion: Circulating immune cells excerpt powerful influences on mood, 
cognition and behavior. An obvious example is the experience of most 
human with “sickness syndrome”, characterized by apathy, avolition, and 
withdrawal, and triggered by immune-cell-released cytokines producing an 
adaptive, resource conserving, behavioral response. While at an early stage, 
our findings further implicate immune system dysregulation as a mechan-
ism in the development of psychosis.
39.2 VIRAL EXPOSURES AND SCHIZOPHRENIA
Faith Dickerson*,1, Robert Yolken2
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Background: Epidemiological, immunological, and microbiological stud-
ies indicate that infections with members of  the family Herpesviridae 
may be associated with schizophrenia and with cognitive impairment. 
Herpesviruses are enveloped, double-stranded DNA viruses which are 
widely prevalent and which are capable of  causing persistent infections. 
The most highly replicated association is that between the alpha herpes-
virus Herpes Simplex Virus Type 1 (HSV-1) and cognitive impairment 
in schizophrenia. Acute HSV-1 infection results in oral lesions which 
usually resolve spontaneously. However, latency can occur in nerve root 
ganglia leading to cycles of  reactivation in later life. Other herepsviruses 
may also be associated with schizophrenia. Epstein Barr virus (EBV) is a 
gamma herpesvirus usually acquired in childhood or adolescence. Acute 
EBV infection is often associated with fever and adenopathy leading to 
a vigorous immune response and the suppression of  viral replication. 
However, latency can occur with long term consequences to the infected 
individual.
Methods: We examined the association between HSV-1 seropositivity 
and cognitive functioning in 828 individuals with schizophrenia from 
the Sheppard Pratt cohort and 573 control individuals. We also studied 
antibodies to EBV in a recently enrolled subset of the Sheppard Pratt 
cohort consisting of 397 individuals with schizophrenia and 289 without 
a psychiatric disorder. Antibodies to HSV-1 and EBV proteins were meas-
ured by immunoassay and confirmed by Western blot. Cognitive func-
tioning was measured by the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS). Regression models were employed 
to define the independent association between virus exposure and outcome.
Results: Serological evidence of exposure to HSV-1 was associated with sig-
nificantly lower levels of cognitive functioning as measured by the RBANS 
Total score (coefficient =-3.84, 95% CI -5.60, -2.09, p<.0001). The strongest 
association was in the domain of Immediate Memory (coefficient= -4.95, 
95% CI -7.24, -2.66, p<.0001.) There was a smaller but statistical signifi-
cant relationship between serological evidence of exposure to HSV-1 and 
RBANS Total score in control individuals. (coefficient =-1.98, 95% CI 
-3.88, -.094, p=.04).
In terms of EBV, we found that individuals with schizophrenia had signif-
icantly higher levels of antibodies to the EBV viral capsid antigens (VCA) 
as compared to controls (coefficient= .57, 95% CI .37- .77, p<1.7 10-8). On 
the other hand, the level of antibody to the EBV Nuclear Antigen (EBNA) 
and EBV Early Antigen (EA) did not differ between the groups. Within the 
schizophrenia group, increased levels of EBV VCA antibodies were asso-
ciated with older age, female gender, and cigarette smoking but not with 
clinical or cognitive measures.
Discussion: The mechanism of the association between HSV-1 exposure 
and cognitive deficits in individuals with schizophrenia may be due to 
